53,076 Shares in Hookipa Pharma Inc (NASDAQ:HOOK) Acquired by Ikarian Capital LLC

Ikarian Capital LLC acquired a new stake in Hookipa Pharma Inc (NASDAQ:HOOK) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 53,076 shares of the company’s stock, valued at approximately $228,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Hookipa Pharma in the 1st quarter valued at approximately $31,000. Renaissance Technologies LLC lifted its position in Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after acquiring an additional 83,800 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after acquiring an additional 108,844 shares in the last quarter. 63.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Royal Bank of Canada lowered their price objective on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. JMP Securities lowered their price target on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st.

Hookipa Pharma Price Performance

Shares of NASDAQ HOOK traded up $0.06 during midday trading on Tuesday, hitting $2.58. 67,528 shares of the stock traded hands, compared to its average volume of 72,263. The firm has a 50-day moving average of $3.57 and a two-hundred day moving average of $5.24. Hookipa Pharma Inc has a one year low of $2.08 and a one year high of $11.30.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.